BIOCRYST PHARMACEUTICALS
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adult and pediatric patients 12 years and older, and under regulatory review for approval in Japan and the European Union. BioCryst has several ongoing development prog... rams including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing.
BIOCRYST PHARMACEUTICALS
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
1986-01-01
Address:
Birmingham, Alabama, United States
Country:
United States
Website Url:
http://www.biocryst.com
Total Employee:
101+
Status:
Active
Contact:
9198591314
Email Addresses:
[email protected]
Total Funding:
1.31 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Google Tag Manager WordPress Content Delivery Network Font Awesome Global Site Tag Sitelinks Search Box IPv6
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2012-10-18 | Presidio Pharmaceuticals | Presidio Pharmaceuticals acquired by BioCryst Pharmaceuticals | 101 M USD |
| 2010-10-14 | Bioanalytical Laboratory Services | Bioanalytical Laboratory Services acquired by BioCryst Pharmaceuticals | N/A |
Investors List
Royalty Pharma
Royalty Pharma investment in Post-IPO Equity - BioCryst Pharmaceuticals
Ontario Municipal Employees Retirement System
Ontario Municipal Employees Retirement System investment in Post-IPO Equity - BioCryst Pharmaceuticals
Royalty Pharma
Royalty Pharma investment in Post-IPO Debt - BioCryst Pharmaceuticals
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Debt - BioCryst Pharmaceuticals
MidCap Financial
MidCap Financial investment in Post-IPO Debt - BioCryst Pharmaceuticals
Centers for Disease Control and Prevention
Centers for Disease Control and Prevention investment in Grant - BioCryst Pharmaceuticals
MidCap Financial
MidCap Financial investment in Post-IPO Debt - BioCryst Pharmaceuticals
National Institutes of Health
National Institutes of Health investment in Post-IPO Equity - BioCryst Pharmaceuticals
National Institute of Allergy and Infectious Diseases
National Institute of Allergy and Infectious Diseases investment in Grant - BioCryst Pharmaceuticals
Key Employee Changes
Official Site Inspections
http://www.biocryst.com Semrush global rank: 2.09 M Semrush visits lastest month: 9.96 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "BioCryst Pharmaceuticals"
About Us - BioCryst®
BioCryst was founded in Birmingham, Alabama, by William Spencer, III, a local businessman; Charles Bugg, ... Oncology Center of Excellence for Parexel, a leading global clinical research …See details»
BioCryst | Canada | Home
BioCryst’s structure-guided drug design involves the integrated application of traditional biology and medicinal chemistry along with an array of advanced technologies, including x-ray crystallography, computer modeling of molecular …See details»
BioCryst Pharmaceuticals - Wikipedia
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China. See details»
Contact Us - BioCryst®
BioCryst Discovery Center of Excellence. 2100 Riverchase Center Building 200, Suite 200 Birmingham, AL 35244 Phone: (205) 444-4600 Fax: (205) 444-4640. BioCryst Ireland Limited …See details»
BioCryst Pharmaceuticals - Crunchbase Company …
BioCryst Pharmaceuticals reported strong financial performance in the first quarter of 2024, exceeding analyst revenue forecasts. The company saw a significant increase in ORLADEYO revenue, which contributed to the positive …See details»
Corporate Responsibility | BioCryst Pharmaceuticals, Inc.
BioCryst’s Board of Directors sets high standards for our employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the …See details»
Org Chart Biocryst Pharmaceuticals - The Official Board
The organizational chart of Biocryst Pharmaceuticals displays its 25 main executives including Jon Stonehouse, Anthony Doyle and Hui Chen. Toggle navigation The Official Board. Search. …See details»
BioCryst Pharmaceuticals, Inc. - Company Profile & Staff Directory ...
BioCryst is a commercial-stage biotech company that is committed to delivering extraordinary medicines that help patients live ordinary lives. We are passionate about advancing novel …See details»
BioCryst Pharmaceuticals Company Profile - Office Locations ...
Oct 29, 2024 BioCryst Pharmaceuticals has 5 employees across 2 locations and $331.41 m in annual revenue in FY 2023. See insights on BioCryst Pharmaceuticals including office …See details»
BioCryst | Canada | Grants
BioCryst are passionate about advancing novel therapeutics for patients with rare and serious diseases. We focus on therapeutic areas with either no available treatments or large unmet …See details»
BioCryst Strengthens Commercial Rare Disease Leadership
“With Charlie’s leadership and experience, BioCryst is well-positioned to deliver berotralstat to patients around the world, as we transform into a fully-integrated commercial organization. He …See details»
BioCryst | Canada | Pipeline
Our development programs represent the potential to improve the well-being of people whose lives are currently limited by rare disease. BioCryst aims to discover novel, oral small-molecule …See details»
BioCryst Pharmaceuticals - Overview, News & Similar companies ...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, …See details»
BioCryst Pharma | Durham NC - Facebook
BioCryst Pharma, Durham, North Carolina. 6,285 likes · 2 talking about this · 1 was here. We develop novel oral medicines for rare diseases to help patients take part in everyday activities.See details»
Patient Advocacy - BioCryst®
Just as we at BioCryst recognize the importance of sharing clinical trial data to advance our research, we also hold patient privacy to the highest standards. Find out more. Clinical trials …See details»
Medical Information & Treatment Access - BioCryst®
BioCryst registers clinical trial information and publishes summary results, regardless of outcome, in accordance with applicable laws and regulations on public registries including …See details»
BioCryst R&D Day Highlights New Diversified Pipeline of First-in …
Nov 3, 2023 BioCryst Pharmaceuticals, Inc. Company builds on deep structure-based drug design capabilities to add protein therapeutics to pipeline: BCX17725 for Netherton syndrome …See details»
BioCryst Reports Second Quarter 2024 Financial Results and …
Aug 5, 2024 —Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously …See details»
Product Pipeline - BioCryst®
For someone living with a rare disease, the concept of being able to go about life without a constant reminder of their condition would represent a world of difference.Restoring a new …See details»